“I am incredibly proud of our team and their commitment to rapidly and efficiently advancing the PYNNACLE study,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “We are excited by the data emerging from this study and look forward to submitting an NDA in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals Advances Cancer Treatment with Promising Study on PC14586
- Promising Developments in PMV Pharmaceuticals’ Ovarian Cancer Treatment Drive Buy Rating
- PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data
- Promising Phase 2 Trial Results and Strategic Plans Support Buy Rating for PMV Pharmaceuticals